{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:02:46Z","timestamp":1792069366527,"version":"4.4.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CAMIn University-Hospital Federation Cancer, Microenvironment"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Circulating tumor DNA (ctDNA) has become an attractive biomarker in human oncology, and its use may be informative in canine cancer. Thus, we used droplet digital PCR or PCR for antigen receptor rearrangement, to explore tumor-specific point mutations, copy number alterations, and chromosomal rearrangements in the plasma of cancer-affected dogs. We detected ctDNA in 21\/23 (91.3%) of histiocytic sarcoma (HS), 2\/8 (25%) of oral melanoma, and 12\/13 (92.3%) of lymphoma cases. The utility of ctDNA in diagnosing HS was explored in 133 dogs, including 49 with HS, and the screening of recurrent <jats:italic>PTPN11<\/jats:italic> mutations in plasma had a specificity of 98.8% and a sensitivity between 42.8 and 77% according to the clinical presentation of HS. Sensitivity was greater in visceral forms and especially related to pulmonary location. Follow-up of four dogs by targeting lymphoma-specific antigen receptor rearrangement in plasma showed that minimal residual disease detection was concordant with clinical evaluation and treatment response. Thus, our study shows that ctDNA is detectable in the plasma of cancer-affected dogs and is a promising biomarker for diagnosis and clinical follow-up. ctDNA detection appears to be useful in comparative oncology research due to growing interest in the study of natural canine tumors and exploration of new therapies.<\/jats:p>","DOI":"10.1038\/s41598-020-80332-y","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T11:26:43Z","timestamp":1610537203000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Circulating tumor DNA is detectable in canine histiocytic sarcoma, oral malignant melanoma, and multicentric lymphoma"],"prefix":"10.1038","volume":"11","author":[{"given":"Ana\u00efs","family":"Prouteau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me Alexandre","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"De Fornel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Cadieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Derrien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Kergal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Botherel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Ulv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Rault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Bouzidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Dorso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Lespagnol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Devauchelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Abadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"H\u00e9dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"80332_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cancergen.2018.02.005","volume":"228\u2013229","author":"CM Stewart","year":"2018","unstructured":"Stewart, C. M. & Tsui, D. W. Y. Circulating cell-free DNA for non-invasive cancer management. Cancer Genet. 228\u2013229, 169\u2013179 (2018).","journal-title":"Cancer Genet."},{"key":"80332_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.gde.2016.12.003","volume":"42","author":"TM Butler","year":"2017","unstructured":"Butler, T. M., Spellman, P. T. & Gray, J. Circulating-tumor DNA as an early detection and diagnostic tool. Curr. Opin. Genet. Dev. 42, 14\u201321 (2017).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"80332_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.phrs.2018.08.017","volume":"136","author":"G De Rubis","year":"2018","unstructured":"De Rubis, G., Krishnan, S. R. & Bebawy, M. Circulating tumor DNA\u2014Current state of play and future perspectives. Pharmacol. Res. 136, 35\u201344 (2018).","journal-title":"Pharmacol. Res."},{"key":"80332_CR4","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","volume":"36","author":"JD Merker","year":"2018","unstructured":"Merker, J. D. et al. Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of American pathologists joint review. J. Clin. Oncol. 36, 1631\u20131641 (2018).","journal-title":"J. Clin. Oncol."},{"key":"80332_CR5","first-page":"241","volume":"142","author":"P Mandel","year":"1948","unstructured":"Mandel, P. & Metais, P. Les acides nucleiques du plasma sanguin chez 1 homme. C. R. Seances Soc. Biol. Fil. 142, 241\u2013243 (1948).","journal-title":"C. R. Seances Soc. Biol. Fil."},{"key":"80332_CR6","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1373\/clinchem.2007.101030","volume":"54","author":"K Saukkonen","year":"2008","unstructured":"Saukkonen, K. et al. Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock. Clin. Chem. 54, 1000\u20131007 (2008).","journal-title":"Clin. Chem."},{"key":"80332_CR7","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1007\/s00134-007-0686-z","volume":"33","author":"K Saukkonen","year":"2007","unstructured":"Saukkonen, K. et al. Association of cell-free plasma DNA with hospital mortality and organ dysfunction in intensive care unit patients. Intensive Care Med. 33, 1624\u20131627 (2007).","journal-title":"Intensive Care Med."},{"key":"80332_CR8","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nrc3066","volume":"11","author":"H Schwarzenbach","year":"2011","unstructured":"Schwarzenbach, H., Hoon, D. S. B. & Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11, 426\u2013437 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"80332_CR9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12885-017-3424-0","volume":"17","author":"JH van Ginkel","year":"2017","unstructured":"van Ginkel, J. H., Huibers, M. M. H., van Es, R. J. J., de Bree, R. & Willems, S. M. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients. BMC Cancer 17, 428 (2017).","journal-title":"BMC Cancer"},{"key":"80332_CR10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40291-017-0260-5","volume":"21","author":"KT Yeung","year":"2017","unstructured":"Yeung, K. T., More, S., Woodward, B., Velculescu, V. & Husain, H. Circulating tumor DNA for mutation detection and identification of mechanisms of resistance in non-small cell lung cancer. Mol. Diagn. Ther. 21, 375\u2013384 (2017).","journal-title":"Mol. Diagn. Ther."},{"key":"80332_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ctrv.2019.07.002","volume":"78","author":"T-H Wu","year":"2019","unstructured":"Wu, T.-H., Hsiue, E.H.-C. & Yang, J.C.-H. Opportunities of circulating tumor DNA in lung cancer. Cancer Treat. Rev. 78, 31\u201341 (2019).","journal-title":"Cancer Treat. Rev."},{"key":"80332_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11864-016-0425-1","volume":"17","author":"M Kwok","year":"2016","unstructured":"Kwok, M., Wu, S. P., Mo, C., Summers, T. & Roschewski, M. Circulating tumor DNA to monitor therapy for aggressive B-cell lymphomas. Curr. Treat. Options Oncol. 17, 47 (2016).","journal-title":"Curr. Treat. Options Oncol."},{"key":"80332_CR13","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1373\/clinchem.2016.255315","volume":"62","author":"M Alcaide","year":"2016","unstructured":"Alcaide, M. et al. Multiplex droplet digital pcr quantification of recurrent somatic mutations in diffuse large B-cell and follicular lymphoma. Clin. Chem. 62, 1238\u20131247 (2016).","journal-title":"Clin. Chem."},{"key":"80332_CR14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","volume":"6","author":"C Alix-Panabi\u00e8res","year":"2016","unstructured":"Alix-Panabi\u00e8res, C. & Pantel, K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 6, 479\u2013491 (2016).","journal-title":"Cancer Discov."},{"key":"80332_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/jvim.14901","volume":"32","author":"IJ Wilson","year":"2018","unstructured":"Wilson, I. J. et al. Kinetics of plasma cell-free DNA and creatine kinase in a canine model of tissue injury. J. Vet. Int. Med. 32, 157\u2013164 (2018).","journal-title":"J. Vet. Int. Med."},{"key":"80332_CR16","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1111\/jvim.14808","volume":"31","author":"U Jeffery","year":"2017","unstructured":"Jeffery, U., Ruterbories, L., Hanel, R. & LeVine, D. N. Cell-free DNA and DNase activity in dogs with immune-mediated hemolytic anemia. J. Vet. Intern. Med. 31, 1441\u20131450 (2017).","journal-title":"J. Vet. Intern. Med."},{"key":"80332_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/vec.12592","volume":"27","author":"J-A Letendre","year":"2017","unstructured":"Letendre, J.-A. & Goggs, R. Measurement of plasma cell-free DNA concentrations in dogs with sepsis, trauma, and neoplasia. J. Vet. Emerg. Crit. Care (San Antonio) 27, 307\u2013314 (2017).","journal-title":"J. Vet. Emerg. Crit. Care (San Antonio)"},{"key":"80332_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1354\/vp.40-1-32","volume":"40","author":"RC Burnett","year":"2003","unstructured":"Burnett, R. C. et al. Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes. Vet. Pathol. 40, 32\u201341 (2003).","journal-title":"Vet. Pathol."},{"key":"80332_CR19","doi-asserted-by":"publisher","first-page":"e0169454","DOI":"10.1371\/journal.pone.0169454","volume":"12","author":"G Beffagna","year":"2017","unstructured":"Beffagna, G. et al. Circulating cell-free DNA in dogs with mammary tumors: Short and long fragments and integrity index. PLoS ONE 12, e0169454 (2017).","journal-title":"PLoS ONE"},{"key":"80332_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1476-5829.2007.00122.x","volume":"5","author":"DMW Schaefer","year":"2007","unstructured":"Schaefer, D. M. W. et al. Quantification of plasma DNA as a prognostic indicator in canine lymphoid neoplasia. Vet. Comp. Oncol. 5, 145\u2013155 (2007).","journal-title":"Vet. Comp. Oncol."},{"key":"80332_CR21","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1101\/gr.194449.115","volume":"25","author":"I Elvers","year":"2015","unstructured":"Elvers, I. et al. Exome sequencing of lymphomas from three dog breeds reveals somatic mutation patterns reflecting genetic background. Genome Res. 25, 1634\u20131645 (2015).","journal-title":"Genome Res."},{"key":"80332_CR22","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.3109\/10428194.2011.559802","volume":"52","author":"R Thomas","year":"2011","unstructured":"Thomas, R. et al. Refining tumor-associated aneuploidy through \u2018genomic recoding\u2019 of recurrent DNA copy number aberrations in 150 canine non-Hodgkin lymphomas. Leuk. Lymphoma 52, 1321\u20131335 (2011).","journal-title":"Leuk. Lymphoma"},{"key":"80332_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/1471-2407-11-201","volume":"11","author":"B Hedan","year":"2011","unstructured":"Hedan, B. et al. Molecular cytogenetic characterization of canine histiocytic sarcoma: A spontaneous model for human histiocytic cancer identifies deletion of tumor suppressor genes and highlights influence of genetic background on tumor behavior. BMC Cancer 11, 201 (2011).","journal-title":"BMC Cancer"},{"key":"80332_CR24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10577-019-09606-0","volume":"27","author":"K Kennedy","year":"2019","unstructured":"Kennedy, K. et al. Genome-wide DNA copy number analysis and targeted transcriptional analysis of canine histiocytic malignancies identifies diagnostic signatures and highlights disruption of spindle assembly complex. Chromosome Res. 27, 179\u2013202 (2019).","journal-title":"Chromosome Res."},{"key":"80332_CR25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3390\/genes10070505","volume":"10","author":"M Takada","year":"2019","unstructured":"Takada, M. et al. Activating mutations in PTPN11 and KRAS in canine histiocytic sarcomas. Genes 10, 505 (2019).","journal-title":"Genes"},{"key":"80332_CR26","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/vco.12357","volume":"16","author":"T Thaiwong","year":"2018","unstructured":"Thaiwong, T., Sirivisoot, S., Takada, M., Yuzbasiyan-Gurkan, V. & Kiupel, M. Gain-of-function mutation in PTPN11 in histiocytic sarcomas of Bernese mountain dogs. Vet. Comp. Oncol. 16, 220\u2013228 (2018).","journal-title":"Vet. Comp. Oncol."},{"key":"80332_CR27","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1002\/ijc.32991","volume":"147","author":"B H\u00e9dan","year":"2020","unstructured":"H\u00e9dan, B. et al. PTPN11 mutations in canine and human disseminated histiocytic sarcoma. Int. J. Cancer 147, 1657\u20131665 (2020).","journal-title":"Int. J. Cancer"},{"key":"80332_CR28","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41467-018-08081-1","volume":"10","author":"K Wong","year":"2019","unstructured":"Wong, K. et al. Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma. Nat. Commun. 10, 353 (2019).","journal-title":"Nat. Commun."},{"key":"80332_CR29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/pcmr.12170","volume":"27","author":"M Gillard","year":"2014","unstructured":"Gillard, M. et al. Naturally occurring melanomas in dogs as models for non-UV pathways of human melanomas. Pigment Cell Melanoma Res. 27, 90\u2013102 (2014).","journal-title":"Pigment Cell Melanoma Res."},{"key":"80332_CR30","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10577-014-9444-6","volume":"23","author":"K Poorman","year":"2015","unstructured":"Poorman, K. et al. Comparative cytogenetic characterization of primary canine melanocytic lesions using array CGH and fluorescence in situ hybridization. Chromosome Res. 23, 171\u2013186 (2015).","journal-title":"Chromosome Res."},{"key":"80332_CR31","doi-asserted-by":"publisher","first-page":"e1007589","DOI":"10.1371\/journal.pgen.1007589","volume":"14","author":"WPD Hendricks","year":"2018","unstructured":"Hendricks, W. P. D. et al. Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. PLoS Genet. 14, e1007589 (2018).","journal-title":"PLoS Genet."},{"key":"80332_CR32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/vco.12536","volume":"18","author":"A Prouteau","year":"2020","unstructured":"Prouteau, A. et al. Prognostic value of somatic focal amplifications on chromosome 30 in canine oral melanoma. Vet. Comp. Oncol. 18, 214\u2013223 (2020).","journal-title":"Vet. Comp. Oncol."},{"key":"80332_CR33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3390\/genes10070501","volume":"10","author":"A Prouteau","year":"2019","unstructured":"Prouteau, A. & Andr\u00e9, C. Canine melanomas as models for human melanomas: Clinical, histological, and genetic comparison. Genes 10, 501 (2019).","journal-title":"Genes"},{"key":"80332_CR34","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.vetimm.2014.02.016","volume":"159","author":"D Ito","year":"2014","unstructured":"Ito, D., Frantz, A. M. & Modiano, J. F. Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: Recent progress and applications. Vet. Immunol. Immunopathol. 159, 192\u2013201 (2014).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"80332_CR35","doi-asserted-by":"publisher","first-page":"324ps5","DOI":"10.1126\/scitranslmed.aaf0746","volume":"8","author":"AK LeBlanc","year":"2016","unstructured":"LeBlanc, A. K. et al. Perspectives from man\u2019s best friend: National academy of medicine\u2019s workshop on comparative oncology. Sci. Transl. Med. 8, 324ps5 (2016).","journal-title":"Sci. Transl. Med."},{"key":"80332_CR36","doi-asserted-by":"publisher","first-page":"e0129534","DOI":"10.1371\/journal.pone.0129534","volume":"10","author":"H Mochizuki","year":"2015","unstructured":"Mochizuki, H., Kennedy, K., Shapiro, S. G. & Breen, M. BRAF mutations in canine cancers. PLoS ONE 10, e0129534 (2015).","journal-title":"PLoS ONE"},{"key":"80332_CR37","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.cvsm.2019.05.002","volume":"49","author":"C Wiley","year":"2019","unstructured":"Wiley, C., Wise, C. F. & Breen, M. Novel noninvasive diagnostics. Vet. Clin. N. Am. Small Anim. Pract. 49, 781\u2013791 (2019).","journal-title":"Vet. Clin. N. Am. Small Anim. Pract."},{"key":"80332_CR38","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/j.1939-1676.2002.tb02411.x","volume":"16","author":"LD Garrett","year":"2002","unstructured":"Garrett, L. D., Thamm, D. H., Chun, R., Dudley, R. & Vail, D. M. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J. Vet. Intern. Med. 16, 704\u2013709 (2002).","journal-title":"J. Vet. Intern. Med."},{"key":"80332_CR39","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1939-1676.2001.tb02328.x","volume":"15","author":"AS Moore","year":"2001","unstructured":"Moore, A. S. et al. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. J. Vet. Intern. Med. 15, 348\u2013354 (2001).","journal-title":"J. Vet. Intern. Med."},{"key":"80332_CR40","first-page":"196","volume":"8","author":"K Sorenmo","year":"2010","unstructured":"Sorenmo, K. et al. Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases. Vet. Comp. Oncol. 8, 196\u2013208 (2010).","journal-title":"Vet. Comp. Oncol."},{"key":"80332_CR41","doi-asserted-by":"publisher","first-page":"e75485","DOI":"10.1371\/journal.pone.0075485","volume":"8","author":"J Beck","year":"2013","unstructured":"Beck, J. et al. Genome aberrations in canine mammary carcinomas and their detection in cell-free plasma DNA. PLoS ONE 8, e75485 (2013).","journal-title":"PLoS ONE"},{"key":"80332_CR42","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1177\/1040638719880245","volume":"31","author":"M Tagawa","year":"2019","unstructured":"Tagawa, M., Shimbo, G., Inokuma, H. & Miyahara, K. Quantification of plasma cell-free DNA levels in dogs with various tumors. J. Vet. Diagn. Investig. 31, 836\u2013843 (2019).","journal-title":"J. Vet. Diagn. Investig."},{"key":"80332_CR43","doi-asserted-by":"publisher","first-page":"5866","DOI":"10.1158\/1078-0432.CCR-19-1145","volume":"25","author":"G Lorch","year":"2019","unstructured":"Lorch, G. et al. Identification of recurrent activating HER2 mutations in primary canine pulmonary adenocarcinoma. Clin. Cancer Res. 25, 5866\u20135877 (2019).","journal-title":"Clin. Cancer Res."},{"key":"80332_CR44","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1080\/01652176.2016.1182230","volume":"36","author":"DL Burnett","year":"2016","unstructured":"Burnett, D. L., Cave, N. J., Gedye, K. R. & Bridges, J. P. Investigation of cell-free DNA in canine plasma and its relation to disease. Vet. Q. 36, 122\u2013129 (2016).","journal-title":"Vet. Q."},{"key":"80332_CR45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.21037\/atm.2017.01.32","volume":"5","author":"D Kwapisz","year":"2017","unstructured":"Kwapisz, D. The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?. Ann. Transl. Med. 5, 46 (2017).","journal-title":"Ann. Transl. Med."},{"key":"80332_CR46","doi-asserted-by":"publisher","first-page":"e0144170","DOI":"10.1371\/journal.pone.0144170","volume":"10","author":"H Mochizuki","year":"2015","unstructured":"Mochizuki, H., Shapiro, S. G. & Breen, M. Detection of BRAF mutation in urine DNA as a molecular diagnostic for canine urothelial and prostatic carcinoma. PLoS ONE 10, e0144170 (2015).","journal-title":"PLoS ONE"},{"key":"80332_CR47","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1373\/clinchem.2012.196014","volume":"59","author":"KCA Chan","year":"2013","unstructured":"Chan, K. C. A. et al. Cancer genome scanning in plasma: Detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin. Chem. 59, 211\u2013224 (2013).","journal-title":"Clin. Chem."},{"key":"80332_CR48","volume-title":"Withrow & MacEwen\u2019s Small Animal Clinical Oncology","author":"S Withrow","year":"2012","unstructured":"Withrow, S., Vail, D. & Page, R. Withrow & MacEwen\u2019s Small Animal Clinical Oncology 5th edn. (Elsevier, Amsterdam, 2012).","edition":"5"},{"key":"80332_CR49","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/vco.12524","volume":"18","author":"H Tani","year":"2020","unstructured":"Tani, H. et al. Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099. Vet. Comp. Oncol. 18, 161\u2013168 (2020).","journal-title":"Vet. Comp. Oncol."},{"key":"80332_CR50","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1158\/1535-7163.MCT-17-1273","volume":"17","author":"M Takada","year":"2018","unstructured":"Takada, M. et al. Targeting MEK in a translational model of histiocytic sarcoma. Mol. Cancer Ther. 17, 2439\u20132450 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"80332_CR51","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.vetimm.2013.03.012","volume":"153","author":"F Gentilini","year":"2013","unstructured":"Gentilini, F., Turba, M. E. & Forni, M. Retrospective monitoring of minimal residual disease using hairpin-shaped clone specific primers in B-cell lymphoma affected dogs. Vet. Immunol. Immunopathol. 153, 279\u2013288 (2013).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"80332_CR52","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1476-5829.2009.00200.x","volume":"8","author":"DM Vail","year":"2010","unstructured":"Vail, D. M. et al. Response evaluation criteria for peripheral nodal lymphoma in dogs (v10)\u2014A veterinary cooperative oncology group (VCOG) consensus document. Vet. Comp. Oncol. 8, 28\u201337 (2010).","journal-title":"Vet. Comp. Oncol."},{"key":"80332_CR53","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.vetimm.2005.10.009","volume":"110","author":"K Tamura","year":"2006","unstructured":"Tamura, K. et al. Development of the polymerase chain reaction assay based on the canine genome database for detection of monoclonality in B cell lymphoma. Vet. Immunol. Immunopathol. 110, 163\u2013167 (2006).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"80332_CR54","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.vetimm.2006.11.005","volume":"115","author":"H Yagihara","year":"2007","unstructured":"Yagihara, H. et al. Genomic organization of the T-cell receptor gamma gene and PCR detection of its clonal rearrangement in canine T-cell lymphoma\/leukemia. Vet. Immunol. Immunopathol. 115, 375\u2013382 (2007).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"80332_CR55","unstructured":"Gautier, A. & Ibisch, C. Validation d\u2019un test de clonalit\u00e9 pour le diagnostic des lymphomes canins par analyse mol\u00e9culaire des r\u00e9arrangements du r\u00e9cepteur \u00e0 l\u2019antig\u00e8ne (PARR) (2014)."},{"key":"80332_CR56","unstructured":"Hitte C. & Andr\u00e9 C. Integrated genetic analysis of canine mucosal melanoma from three predisposed breeds. (2019)."},{"key":"80332_CR57","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2460\/ajvr.73.9.1335","volume":"73","author":"P-C Tsai","year":"2012","unstructured":"Tsai, P.-C. & Breen, M. Array-based comparative genomic hybridization-guided identification of reference genes for normalization of real-time quantitative polymerase chain reaction assay data for lymphomas, histiocytic sarcomas, and osteosarcomas of dogs. Am. J. Vet. Res. 73, 1335\u20131343 (2012).","journal-title":"Am. J. Vet. Res."},{"key":"80332_CR58","doi-asserted-by":"publisher","first-page":"85234","DOI":"10.18632\/oncotarget.19076","volume":"8","author":"M Lodrini","year":"2017","unstructured":"Lodrini, M. et al. Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma. Oncotarget 8, 85234\u201385251 (2017).","journal-title":"Oncotarget"},{"key":"80332_CR59","doi-asserted-by":"publisher","unstructured":"G\u00f3mez-Rubio, V. ggplot2\u2014Elegant graphics for data analysis (2nd Edition). J. Stat. Softw. 77. https:\/\/doi.org\/10.18637\/jss.v077.b02 (2017).","DOI":"10.18637\/jss.v077.b02"},{"key":"80332_CR60","unstructured":"Bunn, A. & Korpela, M. An Introduction to dplR. (2015)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80332-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80332-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80332-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T01:45:56Z","timestamp":1670031956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80332-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["80332"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-80332-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]},"assertion":[{"value":"9 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"877"}}